Chimeric Therapeutics Ltd Investor Webinar Transcript
Thank you for standing by, and welcome to today's Chimeric Therapeutics Investor Webinar discussing today's announcement of positive preliminary Phase 1 data for chlorotoxin CAR T in recurrent brain cancer. (Event Instructions) Presenting on behalf of Chimeric today, we have the CEO and Managing Director, Jennifer Chow; and Chief Medical Officer, Dr. Jason Litten. To begin, I'll hand it over to Jen. Please go ahead.
Thanks so much, Matt. And thank you, everybody, for taking the time this morning to join us on very short notice, to discuss the positive data that we are now seeing with CHM 1101, our chlorotoxin CAR T. I can't tell you personally how excited I am to be able to have this investor webinar today to bring everybody up to speed on this data and really to make good on the commitment that we made with this asset to bring this data to you.
So without further ado, I am going to just take you through a few introduction slides and then I'm actually going to turn
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |